Oruka Therapeutics Rises 12% on Psoriasis Trial Results

Why Oruka Therapeutics Stock Is Up Today

Oruka Therapeutics (NASDAQ: ORKA) is up 12% at $89.92 by early afternoon after positive results for experimental drug ORKA-001. The medicine treats moderate-to-severe plaque psoriasis, a chronic condition that causes thick, scaly skin patches. The findings support moving toward a final-stage trial without yet showing how long the response lasts.

What Oruka Therapeutics Inc. Does

Oruka develops lab-made medicines aimed at chronic skin diseases. Its drug candidates are still being studied rather than approved for sale.

ORKA-001 Psoriasis Trial Results

EVERLAST-B was a Phase 2b trial, a mid-stage study that further tests a treatment and its dose. At Week 16, 61% of people receiving 600 mg had completely clear skin, while 86% had at least 90% improvement. Safety was favorable, and results were consistent with an earlier trial.

Oruka Therapeutics Phase 3 Plan

Oruka selected the tested dose as its proposed Phase 3 starting dose and treatment schedule, with trials planned for the first half of 2027. This is the final trial stage before the FDA, the US drug regulator, decides whether to approve a medicine. Oruka is still working out the maintenance plan, so the benefit of less frequent dosing has not been established.

Quick Financial Overview

Oruka funds drug development with $873.6M in cash, cash equivalents, and short-term investments as of June 30, 2026, enough for about seventy-nine months at its latest quarterly spending rate. That balance includes cash and investments that can be turned into money. Its market value, the total worth of its shares, is $5.95B, making it a mid-cap, a company in the middle size range.

Oruka Therapeutics Share Filings

Oruka has a share registration statement and an offering prospectus on record. These documents register securities for possible sale and describe an offering, respectively. They do not establish that a new share sale was announced today.

Oruka Therapeutics Stock Is up 230% This Year

Oruka shares are up 230% over the past year, so today’s gain builds on a longer advance. For perspective, the last daily move this large was eighty-eight sessions ago.

Oruka Therapeutics Next Psoriasis Results

Results for its separate psoriasis drug ORKA-002 are expected in the first quarter of 2027. That mid-stage study will test another part of Oruka’s drug development plans.

Conclusion

Regulatory talks come next for the lead drug; supportive feedback would clear a step toward its final trials, while requests for more work could delay progress. Those trials must test whether lasting skin clearance can support less frequent treatment. Oruka’s cash covers the wait at its latest spending rate.